--- title: "CASI Pharmaceuticals (CASIF) news: delisting and going concern" url: "https://aibio.space/companies/casi-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CASIF delisting and going concern news: CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote. CASI Pharmaceuticals, Inc." --- CASIF CASI Pharmaceuticals, Inc. OTC · China # CASI Pharmaceuticals (CASIF) news CASIF delisting and going concern news Listings · 2026-08-14 ## [CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote](https://aibio.space/news/casi-pharmaceuticals-reports-3-8-million-cash-details-nasdaq-delisting/) CASI Pharmaceuticals had $3.8 million of cash at June 30, 2026, after its ordinary shares left Nasdaq and began quoting on the OTCQB. Its first-half release says recurring operating losses have raised substantial doubt about its ability to continue as a going concern. ## Latest CASI Pharmaceuticals news 1. 2026-04-21 Distress [CASI Pharmaceuticals says 2025 Form 20-F is late, expects going-concern doubt](https://aibio.space/news/casi-pharmaceuticals-says-2025-form-20-f-late-expects-going-concern/) CASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern. ## CASI Pharmaceuticals at a glance - **Ticker**: CASIF - **Listing**: OTC - **Country**: China - **Cash, Dec 31, 2025**: $5.6 million ### Related companies - [Zhong Zhu Healthcare Holding Co.](https://aibio.space/companies/zhong-zhu-healthcare/) SSE: 600568 - [WuXi AppTec Co.](https://aibio.space/companies/wuxi-apptec/) SSE: 603259 - [Shanghai Allist Pharmaceuticals Co.](https://aibio.space/companies/shanghai-allist-pharmaceuticals/) SSE: 688578 - [Jiangsu Kanion Pharmaceutical Co.](https://aibio.space/companies/jiangsu-kanion-pharmaceutical/) SSE: 600557 - [Zhejiang Benli Technology Co.](https://aibio.space/companies/zhejiang-benli-technology/) SZSE: 301065 - [Staidson (Beijing) Biopharmaceuticals Co.](https://aibio.space/companies/staidson-beijing-biopharmaceuticals/) SZSE: 300204 - [Zhejiang Yatai Pharmaceutical Co.](https://aibio.space/companies/zhejiang-yatai-pharmaceutical/) SZSE: 002370 - [Yifan Pharmaceutical Co.](https://aibio.space/companies/yifan-pharmaceutical/) SZSE: 002019 ### Also on OTC - [America Great Health](https://aibio.space/companies/america-great-health/) AAGH - [BIOTRICITY INC.](https://aibio.space/companies/biotricity/) BTCY - [Devonian Health Group](https://aibio.space/companies/devonian-health-dvhgf/) DVHGF - [GB Sciences](https://aibio.space/companies/gb-sciences/) GBLX - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) AWHL - [Plandai Biotechnology](https://aibio.space/companies/plandai-biotechnology/) PLPL ## What CASI Pharmaceuticals does CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States and throughout the world. The company was incorporated in 1991, and in 2012 it shifted its business strategy to China. Its operations are conducted mainly through two subsidiaries, CASI China, headquartered in Beijing, and CASI Wuxi. The company is focused on acquiring, developing and commercializing products in hematology oncology, autoimmune and organ transplant rejection, along with other unmet medical needs. CASI China oversees the company's sales and marketing of EVOMELA and FOLOTYN, and the anticipated commercial activities of its pipeline products, as well as NMPA regulatory activities. The company states that it had 205 full-time employees in China, including a commercial team of 128 hematology and oncology sales and marketing specialists. Because its business focus has shifted from ANDAs to hematology oncology, the company says a substantial investment in GMP manufacturing facilities does not fit its current focus. | Product or program | What it is | Stage | |---|---|---| | EVOMELA | Product whose sales and marketing CASI China oversees | | | FOLOTYN | Product whose sales and marketing CASI China oversees | | Summarised from the company's [20-F filed May 15, 2026](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm). ## CASI Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$20.7 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | [$28.5 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | | Research and development | [$6.3 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | [$8.9 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | | Net income (loss) | [-$48.1 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | [-$39.3 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | | Cash from operations | [-$20.8 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | [-$29.2 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | | Cash and equivalents | [$5.6 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | [$13.5 million](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $5.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CASI Pharmaceuticals Was CASI Pharmaceuticals delisted? Our latest story on this, dated Aug 14, 2026: "CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/casi-pharmaceuticals-reports-3-8-million-cash-details-nasdaq-delisting/). Has CASI Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Aug 14, 2026: "CASI Pharmaceuticals reports $3.8 million cash, details Nasdaq delisting and OTCQB quote". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/casi-pharmaceuticals-reports-3-8-million-cash-details-nasdaq-delisting/). What is the ticker symbol of CASI Pharmaceuticals? CASI Pharmaceuticals, Inc. trades under the ticker CASIF on OTC. Where is CASI Pharmaceuticals listed? CASI Pharmaceuticals, Inc. is listed on OTC. What is the SEC CIK of CASI Pharmaceuticals? The SEC Central Index Key (CIK) for CASI Pharmaceuticals, Inc. is 1962738. Its filings are on SEC EDGAR. How many shares does CASI Pharmaceuticals have outstanding? 20,555,873 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-05-15. Which country or territory is CASI Pharmaceuticals listed under? Our directory records CASI Pharmaceuticals, Inc. under China. What does CASI Pharmaceuticals do? Our directory classifies CASI Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of CASI Pharmaceuticals? The ISIN recorded for CASI Pharmaceuticals, Inc. is KYG1933S1012. Does aibio.space cover CASI Pharmaceuticals? aibio.space lists CASI Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CASI Pharmaceuticals incorporated? SEC records list its state or country of incorporation as E9. What does CASI Pharmaceuticals develop? CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States and throughout the world. The company was incorporated in 1991, and in 2012 it shifted its business strategy to China. What is EVOMELA from CASI Pharmaceuticals? EVOMELA: Product whose sales and marketing CASI China oversees What is FOLOTYN from CASI Pharmaceuticals? FOLOTYN: Product whose sales and marketing CASI China oversees What was CASI Pharmaceuticals's revenue last year? $20.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: CASI Pharmaceuticals Members talk about CASI Pharmaceuticals (CASIF). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CASI Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465926096404/tm2622837d2_ex99-1.htm) 2. 2026-06-23 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000135445726000606/xslF25X02/primary_doc.xml) 3. 2026-04-21 Distress Told the SEC a periodic report would be filed late. SEC Form NT 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465926045634/tm2612344d1_nt20f.htm) 4. 2026-04-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465926045275/tm2611686d2_6k.htm) 5. 2026-02-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465926019440/tm267154d1_ex99-1.htm) 6. 2026-02-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465926017895/tm266361d1_6k.htm) 7. 2026-01-13 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465926003118/tm262912d1_6k.htm) 8. 2025-12-31 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925125300/tm2534488d1_6k.htm) 9. 2025-12-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925124228/tm2534203d1_ex99-1.htm) 10. 2025-12-11 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925120162/tm2533078d1_ex99-1.htm) 11. 2025-11-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925112605/tm2530997d1_ex99-1.htm) 12. 2025-11-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925109186/tm2530719d1_ex99-1.htm) 13. 2025-05-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925045341/tm2514148d1_ex99-1.htm) 14. 2025-03-31 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465925029652/tm2510656d1_ex99-1.htm) 15. 2025-03-31 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000155837025004086/casi-20241231x20f.htm) 16. 2024-12-20 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1962738/000110465924130920/tm2431074d1_f3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:CASIF on TradingView](https://www.tradingview.com/symbols/OTC-CASIF/). ## SEC filings and registration - **SEC name**: CASI Pharmaceuticals, Inc. - **CIK**: 1962738 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CASIF (OTC) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, China, 100025 - **Phone**: 86 10 6561 8789 - **Shares outstanding**: 20,555,873 as of 2025-12-31 (20-F filed 2026-05-15) - **Former names**: CASI Pharmaceuticals Holdings, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926104455/tm2624664d1_6k.htm) filed 2026-09-02 - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926096404/tm2622837d2_6k.htm) filed 2026-08-14 - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926095969/tm2622837d1_6k.htm) filed 2026-08-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926083702/tm2620566d1_6k.htm) filed 2026-07-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926078452/tm2619066d1_6k.htm) filed 2026-06-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926069177/tm2615983d1_6k.htm) filed 2026-06-02 - [20-F](https://www.sec.gov/Archives/edgar/data/1962738/000110465926061632/casif-20251231x20f.htm) filed 2026-05-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1962738/000110465926045529/tm2611686d1_6k.htm) filed 2026-04-20 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001962738), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CASI Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CASIF, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CASI Pharmaceuticals, Inc. - **Ticker**: CASIF - **Listing**: OTC - **Country or territory**: China - **Business scope**: Pharmaceuticals: Major - **ISIN**: KYG1933S1012 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-CASIF/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/casi-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CASI Pharmaceuticals (CASIF) news: delisting and going concern", 2026-10-31, https://aibio.space/companies/casi-pharmaceuticals/